Amendments to the Claims:

Listing of Claims:

Claim 1 (original): A pharmaceutical preparation for treatment of malignancies, which comprises a chemotherapeutic agent selected from the group consisting of: taxol, a derivative thereof, and aromatase inhibitor and TRAIL; and a bisphosphonate for sequential use.

Claim 2 (original): A pharmaceutical preparation according to claim 1 in which the bisphosphonate is an N-bisphosphonate.

Claim 3 (original): A pharmaceutical preparation according to claim 1 in which the bisphosphonate is a compound of formula I



I

wherein

X is hydrogen, hydroxyl, amino, alkanoyl,or an amino group substituted by C_1-C_4 alkyl, or alkanoyl;

R is hydrogen or C_1-C_4 alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.

Claim 4 (original): A pharmaceutical preparation according to claim 1, in which the bisphosphonate is 2-(imidazol-lyl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 5 (original): A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is paclitaxel or letrozole.

Claim 6 (original): A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is TNF-related apoptosis inducing ligand.

Claim 7 (original): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a chemotherapeutic agent selected from: taxol or a derivative thereof or letrozole; followed sequentially by an effective amount of a bisphosphonate.

Claim 8 (original): A method according to claim 7 wherein the bisphosphonate is an N-bisphosphonate.

Claim 9 (original): A method according to claim 7 wherein the bisphosphonate is a compound of formula I



I

wherein

X is hydrogen, hydroxyl, amino, alkanoyl, or an amino group substituted by C_1-C_4 alkyl, or alkanoyl;

R is hydrogen or C_1-C_4 alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles), or a pharmaceutically acceptable salt thereof or any hydrate thereof.

Claim 10 (original): A method according to claim 7 wherein the bisphosphonate is 2-(imidazol-lyl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 11 (original): A method according to claim 7 wherein the chemotherapeutic agent is paclitaxel.

Claim 12 (original): A method according to claim 7 wherein the chemotherapeutic agent is an aromatase inhibitor and is letrozole.

Claim 13 (original): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.

Claim 14 (original): A method according to claim 13 wherein the bisphosphonate is 2-(imidazol-lyl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 15 (original): The sequential use of a chemotherapeutic agent selected from the group consisting of: taxol, a derivative thereof, an aromatase inhibitor and TRAIL; and a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.

Claims 16 - 25 (canceled)

Claim 26 (original): A commercial package comprising a unit dosage form of a bisphosphonate or a pharmaceutically acceptable salt thereof, or any hydrate thereof, and a unit dosage form of a chemotherapeutic agent selected from the group consisting of: taxol, a derivative thereof, an aromatase inhibitor and TRAIL; together with instructions for administering sequential unit doses of said chemotherapeutic agent and said bisphosphonate for the treatment of malignant diseases.